Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
98 hedge funds and large institutions have $436M invested in Stemline Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 23 reducing their positions, and 15 closing their positions.
124% more capital invested
Capital invested by funds: $195M → $436M (+$241M)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
83% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 23
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
7% more funds holding
Funds holding: 92 → 98 (+6)
87% less call options, than puts
Call options by funds: $365K | Put options by funds: $2.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$34M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$31.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$22.6M |
| 4 |
Goldman Sachs
New York
|
+$15M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$11M |
| 2 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$8.15M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.95M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$4.55M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Dimensional Fund Advisors
Austin,
Texas
| – | -$1.76M | -185,395 | Closed |
|
102
Two Sigma Investments
New York
| – | -$702K | -73,852 | Closed |
|
103
Marshall Wace
London,
United Kingdom
| – | -$254K | -26,763 | Closed |
|
104
D.E. Shaw & Co
New York
| – | -$168K | -17,675 | Closed |
|
|
QSS
105
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
| – | -$167K | -17,604 | Closed |
|
106
AQR Capital Management
Greenwich,
Connecticut
| – | -$125K | -13,138 | Closed |
|
107
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$108K | -11,400 | Closed |
|
|
MWNA
108
Marshall Wace North America
New York
| – | -$32K | -3,324 | Closed |
|
|
MAM
109
Meeder Asset Management
Dublin,
Ohio
| – | -$8K | -790 | Closed |
|
|
AIC
110
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$4K | -427 | Closed |
|
111
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$4K | -406 | Closed |
|
|
PWMG
112
Prestige Wealth Management Group
Flemington,
New Jersey
| – | -$1K | -103 | Closed |
|
113
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$271 | +24 | New |
|
STML Hedge Fund Activity: Q1 2019 in Review
98 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2019, worth a combined $436M — up 124% from $195M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new STML positions and 15 closed out — a net gain of 6 holders — while 42 added to existing stakes and 23 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $34M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $11M sold.
- 98 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2019, up from 92 in Q4 2018.
- Funds reported $436M of Stemline Therapeutics, Inc. stock for Q1 2019, up 124% quarter-over-quarter.
- 21 funds opened new Stemline Therapeutics, Inc. positions in Q1 2019 and 15 closed out, a net change of +6 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q1 2019 was Rubric Capital Management (New York), an estimated $34M added.
- The largest Stemline Therapeutics, Inc. seller in Q1 2019 was Consonance Capital Management, an estimated $11M sold.
Based on aggregated 13F filings for Q1 2019.